Doxycycline eye treatment for persistent wet macular degeneration fluid
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests whether an “MMP-9 inhibitor” medicine given as doxycycline (a tetracycline-type antibiotic) can reduce persistent leaking and fluid in wet age-related macular degeneration. It may help people whose wet AMD is not fully controlled even after several anti-VEGF injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have wet age-related macular degeneration affecting the retina (wAMD).
- You’re being treated with anti-VEGF eye injections, and the leaking disease is still active after at least 3 back-to-back injections.
- You still have persistent retinal fluid seen on eye imaging (with or without other fluid) from the wet AMD area.
- You have NOT had bad side effects from tetracycline medicines (the study uses doxycycline).
- You can return for required follow-up visits at about 6 and 9 months.
- You are able to stay on the study injection plan and not need an urgent change to other treatments during the 9 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye drop called NT-101 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if the drops can improve vision and reduce fluid in the eye, possibly as a less invasive alternative to injections.
This trial tests a new eye injection to treat wet age-related macular degeneration (AMD), a condition that can cause blurry vision. The study checks if the injection is safe and helpful for people with active AMD.
This study tests an investigational drug given as an eye injection to treat wet age-related macular degeneration (AMD) in people who have not been treated before. The goal is to see if it can help improve vision and reduce the need for frequent injections.
This study tests a new medicine given as an eye injection to treat wet age-related macular degeneration (AMD), a condition that causes blurry or lost vision. The treatment aims to improve vision by targeting abnormal blood vessels in the eye.
This trial tests an experimental oral tablet for people with wet age-related macular degeneration. It may offer a new way to treat the condition without frequent eye injections.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.